Critical Illness Myopathy: Glucocorticoids revisited?

Z'Graggen, Werner J.; Schefold, Joerg C. (2019). Critical Illness Myopathy: Glucocorticoids revisited? Acta physiologica, 225(2), e13205. Blackwell Publishing 10.1111/apha.13205

Preview

Text 2018 - Z'Graggen - Acta Physiol - PMID 30338655.pdf - Accepted Version Available under License Publisher holds Copyright. Download (72kB) | Preview

Over the past decades, survival rates of critical illness have constantly increased. As a consequence, the incidences of important complications of intensive care unit (ICU) treatment become more and more prevalent. Critical illness myopathy (CIM) belongs to one of the most frequent neuromuscular complications and its presence is associated with prolonged need for mechanical ventilation and ICU stay, increased morbidity and mortality 1,2. High-dose glucocorticoid (GC) treatment was early after the initial description of CIM postulated to be a major triggering factor for the development of the disease. In the current issue of Acta Physiologica, Akkad et al. investigate the effects of two GC drugs (prednisolone and a new dissociative GC termed vamorolone) on CIM development3. This article is protected by copyright. All rights reserved.

Interest & Impact

Downloads

146 since deposited on 23 Oct 2018
28 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item